The combination of ATR inhibitors with PARP inhibitors, specifically AZD-6738 and olaparib, has been found to effectively target BRAFV600 mutant melanoma cell lines that have developed either primary or acquired resistance to BRAF and MEK inhibitors, demonstrating a high susceptibility to this treatment strategy [154]. The gene discussed is MAP2K7; the disease is melanoma.